Henshaw Capital’s Edwards Lifesciences EW Stock Holding History

Henshaw Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,523	Closed	-$230K	–	359
2020 Q4	$230K	Buy	+2,523	New	+$209K	0.02%	306

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Henshaw Capital's EW Position: Q1 2021 in Review

Henshaw Capital sold out of Edwards Lifesciences (EW) in Q1 2021, closing a stake of 2,523 shares — an estimated $230K sold.

Henshaw Capital first reported a position in EW in Q4 2020 and held it in 1 quarter. The position peaked at $230K in Q4 2020. 1,143 funds tracked by Wall St. Rank hold EW as of Q1 2021.

Henshaw Capital reported no remaining Edwards Lifesciences position as of Q1 2021 after selling out during the quarter.
Henshaw Capital sold 2,523 Edwards Lifesciences shares in Q1 2021, an estimated $230K.
Henshaw Capital first reported a position in Edwards Lifesciences in Q4 2020 and held it in 1 quarter.
Henshaw Capital's Edwards Lifesciences position peaked at $230K in Q4 2020.
1,143 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on Henshaw Capital's 13F filing for Q1 2021, filed 28 May 2026.